ACTH Peptides for Acute Respiratory Distress Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) are not highly effective, leading to significant morbidity and mortality, and there is a need for new therapeutic approaches to address the severe lung dysfunction and systemic inflammation associated with the condition.
Innovation Solution
Administration of adrenocorticotropic hormone (ACTH) peptides or fragments, such as ACTH1-39, in specific dosing regimens to modulate inflammation and steroidogenesis, thereby alleviating lung damage and improving pulmonary function in individuals with or at risk for ARDS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ARDS are used, then standard care is provided, but treatment effectiveness is low leading to high mortality
Solution Approach 1:
The patent changes the therapeutic parameter by introducing ACTH peptide administration with specific dosing regimens (e.g., initial dose of 2-10 mg followed by maintenance doses). This parameter change transforms the treatment approach from conventional supportive care to targeted hormonal therapy, improving treatment effectiveness and reducing mortality in ARDS patients
Solution Approach 2:
ACTH peptide serves as an intermediary substance that mediates the treatment effect by stimulating endogenous corticosteroid production through the HPA axis. This intermediary approach allows indirect modulation of inflammation without direct corticosteroid administration, addressing the limitation of current treatments
2Object-affected harmful factors
If ACTH peptide is administered to treat ARDS, then inflammation is reduced and lung function improves, but steroidogenic effects may occur
Solution Approach 1:
The patent employs preliminary action by administering ACTH peptide before severe steroidogenic complications develop. The dosing regimen is carefully controlled to stimulate sufficient anti-inflammatory response while preventing excessive corticosteroid production, thereby reducing inflammation effectively while minimizing harmful steroidogenic side effects
Solution Approach 2:
The treatment uses periodic dosing regimens with specific intervals (e.g., initial daily doses followed by tapered maintenance doses). This periodic administration pattern maintains therapeutic anti-inflammatory effects while allowing endogenous hormone levels to normalize between doses, reducing the risk of harmful steroidogenic accumulation
Data Source
AI summary
Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH). or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.